We examined the contribution of CD81 to the pathology of IBD using anti-mouse CD81 antibodies and 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis to determine its therapeutic potential for IBD. This evidence concerns the gene CD81 and colitis.